Is This a 737 Max Moment for Brolucizumab?
作者信息
Rosenfeld Philip J, Browning David J
机构信息
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina, USA.
出版信息
Am J Ophthalmol. 2020 Aug;216:A7-A8. doi: 10.1016/j.ajo.2020.05.012. Epub 2020 May 25.
Abstract
摘要
相似文献
1
Is This a 737 Max Moment for Brolucizumab?
Am J Ophthalmol. 2020 Aug;216:A7-A8. doi: 10.1016/j.ajo.2020.05.012. Epub 2020 May 25.
2
Differing Risks of Occlusive Retinal Vasculitis with Concurrent Intraocular Inflammation Among Intravitreal Antivascular Endothelial Growth Factor Therapies.
Retina. 2021 Apr 1;41(4):669-670. doi: 10.1097/IAE.0000000000003015.
3
Drug-related adverse effects of antivascular endothelial growth factor agents.
Curr Opin Ophthalmol. 2021 May 1;32(3):191-197. doi: 10.1097/ICU.0000000000000757.
4
Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity.
JAMA Ophthalmol. 2020 Oct 1;138(10):1103-1104. doi: 10.1001/jamaophthalmol.2020.2810.
5
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
6
[Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration].
Ophthalmologe. 2022 Jan;119(1):75-78. doi: 10.1007/s00347-021-01323-6. Epub 2021 Feb 11.
7
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
8
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System.
Ophthalmic Surg Lasers Imaging Retina. 2018 Dec 1;49(12):913-917. doi: 10.3928/23258160-20181203-01.
9
Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration.
Acta Ophthalmol. 2012 Dec;90(8):e647-8. doi: 10.1111/j.1755-3768.2012.02421.x. Epub 2012 Apr 10.
10
Brolucizumab (Beovu) for age-related macular degeneration.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):23-24.
引用本文的文献
1
Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD.
J Vitreoretin Dis. 2025 Apr 21:24741264251332515. doi: 10.1177/24741264251332515.
2
Evaluating Faricimab in Treatment-Naive Neovascular Age Related Macular Degeneration: A Retrospective Analysis of Real-World Data.
Clin Ophthalmol. 2024 Oct 7;18:2821-2829. doi: 10.2147/OPTH.S468458. eCollection 2024.
3
Inflammation and Vasculitis Related to Brolucizumab.
J Clin Med. 2024 Sep 2;13(17):5208. doi: 10.3390/jcm13175208.
4
Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network.
Sci Rep. 2023 Apr 6;13(1):5639. doi: 10.1038/s41598-023-32398-7.
5
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice.
Front Pharmacol. 2021 Nov 4;12:720345. doi: 10.3389/fphar.2021.720345. eCollection 2021.
6
Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration.
Transl Vis Sci Technol. 2021 Jun 1;10(7):30. doi: 10.1167/tvst.10.7.30.
7
Age-related macular degeneration.
Nat Rev Dis Primers. 2021 May 6;7(1):31. doi: 10.1038/s41572-021-00265-2.
8
[Vaso-occlusive retinitis following intravitreal injection of brolucizumab].
Ophthalmologe. 2021 Oct;118(10):1048-1050. doi: 10.1007/s00347-020-01253-9. Epub 2020 Nov 3.
9
Comment on: Is this a 737 Max Moment for Brolucizumab.
Am J Ophthalmol. 2021 Mar;223:446. doi: 10.1016/j.ajo.2020.06.035. Epub 2020 Sep 15.
本文引用的文献
1
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
2
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.
Am J Ophthalmol Case Rep. 2020 Apr 2;18:100687. doi: 10.1016/j.ajoc.2020.100687. eCollection 2020 Jun.
3
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.
Am J Ophthalmol Case Rep. 2020 Mar 31;18:100680. doi: 10.1016/j.ajoc.2020.100680. eCollection 2020 Jun.
4
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Jul;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031. Epub 2020 Jan 17.
5
Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.
Ophthalmology. 2016 Jul;123(7):1511-20. doi: 10.1016/j.ophtha.2016.02.046. Epub 2016 Apr 12.
6
A Prospective Masked Clinical Assessment of Inflammation After Intravitreal Injection of Ranibizumab or Aflibercept.
J Ocul Pharmacol Ther. 2016 May;32(4):216-8. doi: 10.1089/jop.2015.0152. Epub 2016 Mar 3.
7
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Ophthalmic Epidemiol. 2016;23(2):71-9. doi: 10.3109/09286586.2015.1090004. Epub 2016 Feb 8.
8
Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.
Am J Ophthalmol. 2014 Oct;158(4):733-737.e1. doi: 10.1016/j.ajo.2014.06.019. Epub 2014 Jun 28.
9
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.
10
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
Zotero 插件